Co-Diagnostics Reports Staggering $35.25/Share Loss for 2025, Revenue Plummets
CODX is trading near its 52-week low of $1.66 (12% above the low) on light trading volume (0.2× avg).
Summary
Co-Diagnostics reported a staggering net loss of $46.9 million, or $35.25 per share, for the full year 2025, a significant deterioration from the $37.6 million loss in 2024. Revenue plummeted to $0.6 million from $3.9 million, while cash reserves declined from $29.7 million to $11.9 million. This follows a recent Reuters report expecting a substantial Q4 2025 loss, but the actual full-year results reveal a far more severe financial situation, with the per-share loss being many multiples of the current stock price. The reported net loss is over ten times the company's current market capitalization, indicating extreme financial distress and an unsustainable burn rate. This level of loss, coupled with declining revenue and cash, raises significant going concern issues and presents an immediate and critical risk to the company's viability. Investors will be closely watching for any further capital raises or strategic changes.
At the time of this announcement, CODX was trading at $1.86 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.66 to $46.50. This news item was assessed with negative market sentiment and an importance score of 10 out of 10. Source: Dow Jones Newswires.